Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
The phase 3 OCEAN study evaluated Pepaxto in combination with low-dose dexamethasone in adults with relapsed or refractory multiple myeloma following 2 to 4 lines of prior therapy and who were refractory to lenalidomide in the last line of therapy.
Researchers sought to determine whether acalabrutinib, venetoclax, and obinutuzumab would be a helpful option for frontline treatment of CLL.
Stopping treatment after induction did not impact disease-free survival in patients with undetectable minimal residual disease.
Differentiation syndrome is a potentially severe complication in AML, although prompt management is usually effective and rarely requires cessation of targeted therapy.
Researchers sought to determine whether genomic evaluation in patients with BCR-ABL1 negative B-ALL may improve risk assessments.
The primary outcome measure is progression-free survival.
The study’s primary outcome is progression-free survival by independent review.
The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
The trial’s primary objective is to compare the incidence of major infections.
The primary outcome measure is overall response rate.
Researchers sought to determine whether higher-intensity thromboprophylaxis may be necessary for reducing the risk of VTE in younger patients with multiple myeloma.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Hispanic patients had significantly higher rates of severe cytokine release syndrome.
Researchers sought to determine whether salvage therapy with high-dose chemotherapy followed by ASCT would improve survival in patients with MM.
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
Researchers sought to determine whether patients with B-NHL who had treatment with anti-CD20 antibodies had an impaired serological response to an mRNA COVID-19 vaccine.
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
Transplant improved progression-free and overall survival at a median follow-up of 14 years.
Time to next treatment was significantly longer with brentuximab vedotin.